Gilead released data showing that an HIV drug, called lenacapavir, could provide virtually complete protection against ...

Gilead (NASDAQ:GILD) on Tuesday announced encouraging initial data from an ongoing Phase 1 trial for lenacapavir, an ...

After Gilead’s lenacapavir made waves with stellar clinical results as a twice-yearly HIV prevention candidate, the drug has ...

Sciences presented the first data from its ongoing Phase 1 study investigating two novel, once-yearly formulations of ...

Academy Award winning filmmaker Martin Scorsese ( Taxi Driver , Goodfellas , Killers of the Flower Moon ) has signed on to ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Morgan Stanley analyst Terence Flynn raised the firm’s price target on Gilead (GILD) to $130 from $123 and keeps an Overweight rating on the ...

After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price ...

Gilead Sciences set aside $200 million for a potential settlement with federal prosecutors to resolve an investigation into ...